- Home
- IVA vs BGH Comparison
IVA vs BGH Comparison
Compare IVA & BGH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVA
- BGH
- Stock Information
- Founded
- IVA 2011
- BGH 2012
- Country
- IVA France
- BGH United States
- Employees
- IVA N/A
- BGH N/A
- Industry
- IVA Biotechnology: Pharmaceutical Preparations
- BGH Investment Managers
- Sector
- IVA Health Care
- BGH Finance
- Exchange
- IVA Nasdaq
- BGH Nasdaq
- Market Cap
- IVA 359.6M
- BGH 318.8M
- IPO Year
- IVA 2020
- BGH N/A
- Fundamental
- Price
- IVA $5.32
- BGH $16.61
- Analyst Decision
- IVA Strong Buy
- BGH
- Analyst Count
- IVA 6
- BGH 0
- Target Price
- IVA $15.33
- BGH N/A
- AVG Volume (30 Days)
- IVA 71.1K
- BGH 61.5K
- Earning Date
- IVA 09-26-2025
- BGH 01-01-0001
- Dividend Yield
- IVA N/A
- BGH 10.06%
- EPS Growth
- IVA N/A
- BGH N/A
- EPS
- IVA N/A
- BGH N/A
- Revenue
- IVA $14,591,573.00
- BGH N/A
- Revenue This Year
- IVA $80.35
- BGH N/A
- Revenue Next Year
- IVA N/A
- BGH N/A
- P/E Ratio
- IVA N/A
- BGH N/A
- Revenue Growth
- IVA N/A
- BGH N/A
- 52 Week Low
- IVA $1.53
- BGH $11.92
- 52 Week High
- IVA $6.50
- BGH $14.50
- Technical
- Relative Strength Index (RSI)
- IVA 58.63
- BGH 67.88
- Support Level
- IVA $5.27
- BGH $15.76
- Resistance Level
- IVA $5.75
- BGH $16.63
- Average True Range (ATR)
- IVA 0.39
- BGH 0.13
- MACD
- IVA 0.03
- BGH 0.03
- Stochastic Oscillator
- IVA 50.66
- BGH 97.93
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.
About BGH Barings Global Short Duration High Yield Fund of Beneficial Interests
Barings Global Short Duration High Yield Fund is a diversified, closed-end management investment company. Its investment objective is to seek as high a level of current income as the Adviser determines is consistent with capital preservation.